This formulary decision guide was developed from content provided by Almirall Ltd in a format developed by Guidelines in Practice. It was commissioned by Almirall Ltd, who carried out full medical approval to ensure compliance with regulations.
View prescribing and adverse event reporting information
UK-KLI-2100017 | Date of preparation: October 2021
Disease-modifying anti-rheumatic drugs (DMARDS) guidelines: a focus on methotrexate guidance in clinical practice
Information intended for UK healthcare professionals only. This webinar was initiated and commissioned by Accord-UK Ltd and developed in partnership with Guidelines in Practice.
View Methofill® (methotrexate) pre-filled injector and pre-filled syringe prescribing information and adverse event reporting information here
View the Summary of Product Characteristics for Folic Acid 5mg Tablets; Legal Cat POM; NHS List price 90p
Date of preparation: September 2021
Information intended for UK healthcare professionals only.
Methofill® (methotrexate) SelfDose for the treatment of adult patients with rheumatoid arthritis, Crohn’s disease, and psoriasis*
Intended for UK Healthcare professionals only.
This promotional supplement has been commissioned and funded by Accord-UK Ltd and developed in partnership with Guidelines in Practice.
Click here for Methofill® (methotrexate) prescribing information and adverse event reporting
For full indications, please consult the summary of product characteristics.
UK-03037 | Date of preparation: May 2021
This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines.
Date of preparation: January 2021